Bioelectrochemical platform with human monooxygenases: FMO1 and CYP3A4 tandem reactions with phorate

被引:5
|
作者
Cheropkina, Hanna [1 ]
Catucci, Gianluca [1 ]
Cesano, Federico [2 ,3 ,4 ]
Marucco, Arianna [1 ]
Gilardi, Gianfranco [1 ,4 ]
Sadeghi, Sheila J. [1 ,4 ]
机构
[1] Univ Torino, Dept Life Sci & Syst Biol, via Acad Albertina, I-10123 Turin, Italy
[2] Dept Chem, Via Giuria 7, I-10125 Turin, Italy
[3] INSTM UdR Torino, Via Giuria 7, I-10125 Turin, Italy
[4] Univ Torino, Ctr Nanostruct Interfaces & Surfaces, Via Pietro Giuria 7, I-10125 Turin, Italy
关键词
AFM; Flavoprotein; Biocatalysis; Graphene oxide; Methiocarb; Phorate; Fenthion; FLAVIN-CONTAINING MONOOXYGENASE; GRAPHENE OXIDE; HUMAN CYTOCHROME-P450; DRUG-METABOLISM; THIOETHER COMPOUNDS; PESTICIDE EXPOSURE; SURFACES; RISK; ORGANOPHOSPHORUS; SULFOXIDATION;
D O I
10.1016/j.bioelechem.2022.108327
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It is highly advantageous to devise an in vitro platform that can predict the complexity of an in vivo system. The first step of this process is the identification of a xenobiotic whose monooxygenation is carried out by two sequential enzymatic reactions. Pesticides are a good model for this type of tandem reactions since in specific cases they are initially metabolised by human flavin-containing monooxygenase 1 (hFMO1), followed by cyto-chrome P450 (CYP). To assess the feasibility of such an in vitro platform, hFMO1 is immobilised on glassy carbon electrodes modified with graphene oxide (GO) and cationic surfactant didecyldimethylammonium bromide (DDAB). UV-vis, contact angle and AFM measurements support the effective decoration of the GO sheets by DDAB which appear as 3 nm thick structures. hFMO1 activity on the bioelectrode versus three pesticides; fen-thion, methiocarb and phorate, lead to the expected sulfoxide products with KM values of 29.5 +/- 5.1, 38.4 +/- 7.5, 29.6 +/- 4.1 mu M, respectively. Moreover, phorate is subsequently tested in a tandem system with hFMO1 and CYP3A4 resulting in both phorate sulfoxide as well as phoratoxon sulfoxide. The data demonstrate the feasibility of using bioelectrochemical platforms to mimic the complex metabolic reactions of xenobiotics within the human body.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites
    Sutton, D
    Butler, AM
    Nadin, L
    Murray, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1997, 282 (01): : 294 - 300
  • [32] Time-dependent inhibition of CYP3A4 by mibefradil in recombinant CYP3A4 and human liver microsomes and impact on in vivo predictions
    Burt, Howard
    Galetin, Aleksandra
    Houston, Brian
    DRUG METABOLISM REVIEWS, 2006, 38 : 47 - 48
  • [33] Screening of Human CYP1A2 and CYP3A4 Inhibitors from Seaweed In Silico and In Vitro
    Yim, Sung-Kun
    Kim, Kian
    Chun, SangHo
    Oh, TaeHawn
    Jung, WooHuk
    Jung, KyooJin
    Yun, Chul-Ho
    MARINE DRUGS, 2020, 18 (12)
  • [34] Inhibition of CYP3A4 by 6′,7′-dihydroxybergamottin in human CYP3A4 over-expressed hepG2 cells
    Araki, Nobutaka
    Tsuruoka, Shuichi
    Hasegawa, Gohki
    Yanagihara, Hayato
    Omasa, Takeshi
    Enosawa, Shin
    Yamazoe, Yasushi
    Fujimura, Akio
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 64 (12) : 1715 - 1721
  • [35] Quantitative RT-PCR for CYP3A4 mRNA in human peripheral lymphocytes: induction of CYP3A4 in lymphocytes and in liver by rifampicin
    Nakamoto, T
    Hase, I
    Imaoka, S
    Hiroi, T
    Oda, Y
    Asada, A
    Funae, Y
    PHARMACOGENETICS, 2000, 10 (06): : 571 - 575
  • [36] CYP1A1 and CYP3A4 modulation by dietary flavonoids in human intestinal Caco-2 cells
    Sergent, Therese
    Dupont, Isabelle
    Van der Heiden, Edwige
    Scippo, Marie-Louise
    Pussemier, Luc
    Larondelle, Yvan
    Schneider, Yves-Jacques
    TOXICOLOGY LETTERS, 2009, 191 (2-3) : 216 - 222
  • [37] Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4*1G and CYP3A metabolism
    Collins, Joseph M.
    Wang, Danxin
    PHARMACOGENETICS AND GENOMICS, 2022, 32 (01): : 16 - 23
  • [38] Detection of CYP3A4*1B and CYP3A4*2 polymorphisms by RFLP.: Distribution frequencies in a Mexican population
    Reyes-Hernández, OD
    Arteaga-Illán, G
    Elizondo, G
    CLINICAL GENETICS, 2004, 66 (02) : 166 - 168
  • [39] Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant
    Hannachi, Ibtissem
    Ben Fredj, Nadia
    Chadli, Zohra
    Ben Fadhel, Najah
    Ben Romdhane, Haifa
    Touitou, Yvan
    Boughattas, Naceur A.
    Chaabane, Amel
    Aouam, Karim
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 396
  • [40] Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: A possible role of intestinal CYP3A4 expression
    Ufer, M.
    Dilger, K.
    Leschhorn, L.
    Daufresne, L. M.
    Mosyagin, I.
    Rosenstiel, P.
    Haesler, R.
    Kuehbacher, T.
    Nikolaus, S.
    Schreiber, S.
    Cascorbi, I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (01) : 43 - 46